Riepert IT Leverages IP Infusion's OcNOS® Networking Software on UfiSpace Hardware to Deploy High-Performance 100G Fiber Network
Santa Clara, CA – September 30, 2025 – IP Infusion, a global leader in open networking software solutions, announced today that Riepert IT, an Internet Service Provider (ISP) building its own fiber network, has successfully deployed IP Infusion's OcNOS® Service Provider (SP) platform, with support from distribution partner EPS Global, to meet growing bandwidth demands and deliver advanced services to private and corporate clients.
The deployment enables Riepert IT to upgrade its backbone links from 10G to 100G, utilizing UfiSpace S9510-28DC hardware and advanced OcNOS software features such as IS-IS, SR-MPLS, TI-FLA, and EVPN-MPLS. This greenfield deployment provides cost-effective access to modern networking technologies, replacing legacy MikroTik solutions and enabling Riepert IT to offer new, high-value services to its customers.
"IP Infusion's OcNOS gave us the ability to scale our network to meet surging bandwidth demands while keeping costs manageable," said Gerald Riepert, CEO of Riepert IT. "Their clear licensing model and the seamless support from EPS Global made this transformation straightforward and cost-effective. We're now positioned to deliver cutting-edge services to our customers with confidence."
"We're proud to partner with IP Infusion to empower Riepert IT's network evolution," said Chris Curley, Managing Director of Global Networking for EPS Global. "By combining OcNOS's robust open networking capabilities with our streamlined global inventory strategy and multi-vendor support, we've helped Riepert IT achieve a high-performance, scalable network. We are committed to simplifying complexity and mitigating supply chain risks, empowering ISPs like Riepert IT to scale their business confidently and efficiently."
"Riepert IT's successful deployment highlights the power of OcNOS to deliver modern, scalable networking solutions at a fraction of the cost of traditional vendors," said Kiyo Oishi, CEO of IP Infusion. "Working with partners like EPS Global, we're enabling ISPs worldwide to transform their networks and unlock new opportunities for growth and innovation."
Über IP Infusion
IP Infusion develops open network software solutions for carriers, service providers, and data centers. With hundreds of customers and thousands of deployments, IP Infusion leads the market in Network Operating Systems. Its flagship platform, OcNOS®, empowers network operators to disaggregate their networks, streamline operations, and reduce total cost of ownership (TCO). Headquartered in Santa Clara, Calif., IP Infusion is a wholly owned subsidiary of ACCESS CO., LTD. For more information, visit www.ipinfusion.com/.
-end-
Pressekontakt
Katherine Verducci, 1903 PR
kverducci@1903pr.com
408.429.5779
Über IP Infusion
IP Infusion ist ein führender Anbieter von Open-Networking-Software und liefert OcNOS, ein Carrier-Grade-Netzwerkbetriebssystem für Service Provider, Rechenzentren und AI-Fabric-Netze. Mit 26+ Jahren Netzwerkerfahrung und 600+ Operatoren weltweit ermöglicht IP Infusion offene, herstellerübergreifende, kosteneffiziente und flexible Netzwerkinfrastruktur auf validierter offener Hardware von Partnern wie Edgecore Networks, UfiSpace und Celestica. IP Infusion ist eine hundertprozentige Tochtergesellschaft der ACCESS CO., LTD. (Tokyo Stock Exchange: 4813).
Pressekontakt
For press inquiries, analyst briefings, or media materials, please unser Team kontaktieren or email pr@ipinfusion.com.
Zukunftsgerichtete Aussagen
Diese Mitteilung kann zukunftsgerichtete Aussagen zu Produkten, Technologien und Plänen von IP Infusion enthalten. Zukunftsgerichtete Aussagen beruhen auf den zum Veröffentlichungsdatum verfügbaren Informationen und sind mit Risiken und Unsicherheiten verbunden. Die tatsächlichen Ergebnisse können abweichen. Produktpläne, Funktionen, Release-Termine und Verfügbarkeit können sich ohne Vorankündigung ändern und stellen keine Zusage, kein Versprechen und keine rechtliche Verpflichtung dar. IP Infusion übernimmt keine Verpflichtung, zukunftsgerichtete Aussagen zu aktualisieren.